ArticlePLOS global public health2026
Postpartum integration of infant vaccines and contraception through gender transformative programming: A cluster randomized trial in India.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Barriers to using contraception in India include norms that promote gender inequality by restricting mobility of women to reach health clinics. We evaluated whether PIVoT (Postpartum Integration of Vaccines and contraception through gender-Transformative programming) improves contraceptive use while enhancing autonomy in contraceptive decision-making. PIVoT delivers the full spectrum of contraceptive methods available along with gender-transformative counseling, linked with community-based infant vaccination. We conducted a cluster randomized trial; 20 Anganwadi Community centers were randomized to PIVoT or the standard-of-care. We included women 18 years and older, within 12 weeks postpartum, presenting for infant vaccination at community centers in rural Maharashtra, India. We measured contraceptive use (primary outcome) and reproductive autonomy after six months. From September 2023 to June 2024, we enrolled 293 women: 143 at intervention and 150 at control sites. Follow-up at six months was 95%. Any contraceptive use was more common for the control group at baseline (n = 57, 39.9% vs n = 93, 62.0%, p < 0.001) and for the intervention group at follow-up (n = 67, 48.9% vs n = 53, 37.3%, p = 0.051). There was a time-by-treatment effect for any contraceptive use (adjusted ratio of odds ratios 3.98, 95% CI 1.95-8.12). IUD use was slightly higher at six months in the intervention group (2.9% vs 0%, p = 0.04). Use of female-controlled methods (permanent contraception, pills, IUDs, injectables) was higher at six months among the intervention group (13.1% vs 6.3%, p = 0.04). Reproductive decision-making autonomy was higher among intervention participants at follow-up (2.02 vs 1.93, p = 0.02). The PIVoT intervention may increase contraceptive use postpartum, particularly female-controlled methods, while improving reproductive autonomy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.